Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1982-9-24
pubmed:abstractText
1 The blood pressure lowering effect of xipamide, a non-thiazide diuretic given for 6 weeks was compared in a randomised cross-over trial with that of cyclopenthiazide in 14 patients with essential hypertension. 2 Xipamide 10 or 20 mg given once daily was as effective in lowering supine blood pressure as daily cyclopenthiazide 0.5 mg. There was no difference in the blood pressure lowering effect of 10 mg xipamide daily for 2 weeks compared to 20 mg daily given for a further 4 weeks. 3 Plasma potassium was reduced by both drugs, but markedly more after both 10 mg and 20 mg xipamide than after cyclopenthiazide 0.5 mg. By the sixth week of treatment 13 of 14 patients on xipamide but only 6 of 14 on cyclopenthiazide has plasma potassium concentrations of, or less than, 3.5 mmol/l. The fall in plasma potassium was significantly greater and the final plasma potassium concentration was significantly lower after either dose of xipamide than after cyclopenthiazide. 4 These results suggest that 10 mg or 20 mg of xipamide daily is effective in lowering blood pressure in hypertensive patients but is associated with hypokalaemia. In view of recent evidence linking diuretic-induced hypokalaemia with cardiac dysrhythmias in patients with essential hypertension we would suggest that thiazide diuretics be used in preference to xipamide for the routine management of essential hypertension. Our results also suggest that the currently recommended dose of xipamide (20 mg) for the treatment of hypertension is excessive, and lower amounts than 10 mg per day might possibly be as effective in lowering blood pressure with less adverse metabolic consequences.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-1010179, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-1124670, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-1149480, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-1173041, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-1259829, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-14059050, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-332217, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-436356, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-5444227, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-579231, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-679493, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-7388460, http://linkedlifedata.com/resource/pubmed/commentcorrection/7046777-796642
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
859-63
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
Xipamide and cyclopenthiazide in essential hypertension--comparative effects on blood pressure and plasma potassium.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial